Triglyceride Lowering Study (TGLL)

• ClinicalTrials.gov Identifier: NCT00934219
• Recruitment Status: Unknown
• First Posted: July 8, 2009
• Last Update Posted: July 8, 2009
• Sponsor: Jewish Hospital, Cincinnati, Ohio
• Collaborator: GlaxoSmithKline
• Information provided by: Jewish Hospital, Cincinnati, Ohio

Study Description

Brief Summary:

Lovaza is a special fish oil concentrate, that prescribed at 4 g a day to reduce certain fat (triglycerides) levels in blood.Our goal is to study how Lovaza at doses of 4, 8, and 12 grams per day will reduce fats in the blood of the patients with very high level of triglycerides. Our hypothesis is that patients with very high triglycerides will respond more with higher doses of Lovaza (8 g per day and then 12 g per day).

Condition or disease	Intervention/treatment	Phase
Hypertriglyceridemia	Drug: Omega-3-Acid Ethyl Esters	Phase 4

Detailed Description:

Lovaza contains Omega-3 fatty acids, the family of poly- unsaturated fatty acids. Omega-3 fatty acids stimulate blood circulation, increases the breakdown of fibrin, and additionally has been shown to reduce blood pressure, cardiac events and mortality from congestive heart failure. There is strong scientific evidence that omega 3 fatty acids significantly reduce blood triglyceride levels while elevating high density lipoprotein cholesterol (HDL) levels. Fasting and non fasting hypertriglyceridemia have been associated with atherosclerosis, and coronary heart disease events, even in the absence of hypercholesterolemia. Severe hypertriglyceridemia (>2000 mg/dl) can also lead to acute hemorrhagic pancreatitis.

Currently, patients having very High TG are treated with Fibric acids (gemfibrozil, Tricor, Antara), and if hyperinsulinemic, with Glucophage. Lovaza (4g/day) has been shown to be effective and safe in lowering TG levels. There is no published data which indicates that Lovaza 8 or 12 g per day would have therapeutic effectiveness in further normalizing triglycerides in subjects on maximized triglyceride lowering and Lovaza 4 g per day. We hypothesize, based on our clinical experience that increasing Lovaza to 8 and then (if necessary) to 12 g/day would safely optimize triglycerides in subjects with primary hypertriglyceridemia who failed to normalize their triglycerides on optimal therapy including Lovaza 4 g/day.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 25 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza.
• Study Start Date: July 2009
• Estimated Primary Completion Date: July 2012
• Estimated Study Completion Date: December 2012

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: High dose Lovaza; Lovaza 4 g twice a day, if not effective then 4 g 3 times a day	Drug: Omega-3-Acid Ethyl Esters; LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).; Other Name: LOVAZA
Active Comparator: Standard Dose; 2 g twice a day	Drug: Omega-3-Acid Ethyl Esters; LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).; Other Name: LOVAZA

Outcome Measures

Primary Outcome Measures :

1. triglycerides level [ Time Frame: 7 months ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Primary hypertriglyceridemia with fasting TG levels >1000 mg/dl, and persistence of TG levels > 500 mg/dl despite maximal TG lowering therapy for 1 month, including Lovaza 4 g/day, fibric acids, and, where indicated, Glucophage for treatment of hyperinsulinemia.
2. Patients with mild to moderately impaired renal function should be initiated on TRICOR 48 mg and patients with severe renal impairment should not be given TRICOR.
3. Absence of exclusionary criteria (see below).

Exclusion Criteria:

1. Patients with known allergy to fish
2. Hypertriglyceridemia secondary to alcoholism, exogenous estrogens, nephrotic syndrome, hemochromatosis, glycogen storage disease, uncontrolled diabetes, exogenous corticosteroids, Cushing's syndrome, uremia).
3. Bleeding gastric or duodenal ulcers, active inflammatory bowel disease.
4. Pregnancy
5. Dementia
6. Patients with bleeding diatheses
7. Patients who are taking concomitant anticoagulants and other medications that affect bleeding time (e.g., warfarin, aspirin)
8. Patients with significantly abnormal transaminases (above 3x of upper normal limit)or any history of liver disease

9. Patients with conditions affecting the skin (e.g. malignancy, vasculitides) that may confound the skin exam.

   -

Contacts and Locations

Contacts

Contact: LUANN SIEVE; (513)585-7951; luann.sieve@healthall.com

Contact: Naila Goldenberg, MD; (513) 585-7950; naila.goldenberg@healthall.com

Locations

United States, Ohio

Jewish Hospital Cholesterol Center; Recruiting

Cincinnati, Ohio, United States, 45229

Sponsors and Collaborators

Jewish Hospital, Cincinnati, Ohio

GlaxoSmithKline

Investigators

• Principal Investigator: Charles Glueck, MD; JEWISH HOSPITAL CHOLESTEROL CENTER

More Information

Additional Information:

Free Triglycerides lowering study 

• Responsible Party: Charles Glueck, MD Medical director of Cholesterol Center, Jewish Hospital Cholesterol Center
• ClinicalTrials.gov Identifier: NCT00934219
• Other Study ID Numbers: TgLL8506
• First Posted: July 8, 2009
• Last Update Posted: July 8, 2009
• Last Verified: June 2009

Keywords provided by Jewish Hospital, Cincinnati, Ohio:

hypertriglyceridemia; triglycerides; familial hypertriglyceridemia

Additional relevant MeSH terms:

Hypertriglyceridemia; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases